← Eichor
Study identifier: NCT05243719 Synced from ClinicalTrials.gov · July 28, 2026
● Terminated

Open-label Extension Study of ADP101

Condition: Food Allergy  ·  Sponsor: Alladapt Immunotherapeutics, Inc.

PhasePhase 1/Phase 2
Planned participants45
Who can joinAll sexes, 4 Years to 57 Years
Healthy volunteersNo

About this study

This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (14)

Study SiteMission Viejo, California, United States
Study SiteRolling Hills Estates, California, United States
Study SiteSan Diego, California, United States
Study SiteColorado Springs, Colorado, United States
Study SiteDenver, Colorado, United States
Study SiteTampa, Florida, United States
Study SiteAtlanta, Georgia, United States
Study SiteMarietta, Georgia, United States
Study SiteNormal, Illinois, United States
Study SiteAnn Arbor, Michigan, United States
Study SiteChapel Hill, North Carolina, United States
Study SiteCincinnati, Ohio, United States

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05243719